The financial year that just ended on 30 June was a tough one for ASX shares. Over FY 2022, the S&P/ASX 200 Index (ASX: XJO) lost 10.19%. So it goes without saying that any ASX exchange-traded fund (ETF) that tracks the ASX 200 gave investors a similar loss.
But were there any ETFs that did even worse? Let's check out the five worst-performing funds of the year.
Image source: Getty Images
The 5 worst-performing ASX ETFs of FY 2022
BetaShares S&P/ASX Australian Technology ETF (ASX: ATEC)
Our first laggard is this tech-focused fund from provider BetaShares. ATEC tracks one of the newer ASX indexes in the S&P/ASX All Technology Index (ASX: XTX). It holds many of the ASX's largest tech shares, including Xero Limited (ASX: XRO) and Carsales.com Ltd (ASX: CAR).
Unfortunately, ASX tech shares were some of the hardest-hit companies last financial year, as we can see this in this fund's performance. Over FY 2022, ATEC units lost 35.7% of their value.
BetaShares Cloud Computing ETF (ASX: CLDD)
Another BetaShares ETF, CLDD has only been around since February 2021. But it has certainly had a rough time over its short life. As the name implies, this fund focuses on global companies that operate in the cloud computing arena.
You might know some of its larger holdings such as Zoom Video Communications and Netflix. But having such a potent exposure to tech has also hampered CLDD, with this fund losing 35.79% over FY 2022.
BetaShares Global Robotics and Artificial Intelligence ETF (ASX: RBTZ)
Tech is certainly featuring prominently in this list. RBTZ is such an ETF, and one that concentrates on robotics and artificial intelligence companies from around the world. It includes companies such as NVIDIA and Yaskawa Electric Corp. RBTZ took a beating over FY 2022, losing 36.01% for its investors.
ETFS S&P Biotech ETF (ASX: CURE)
A tech ETF of a different kind, this fund from provider ETFS focuses on US biotechnology companies. You'll find COVID-19 vaccine provider Novavax here, as well as Twist Bioscience and Arrowhead Pharmaceuticals. But CURE investors were left wanting in FY 2022, with this fund going backwards by 40.51%.
ETFS Ultra Long NASDAQ 100 Hedge Fund (ASX: LNAS)
Our final and worst-performing ETF of FY 2022 is an index fund of sorts. LNAS tracks the US NASDAQ-100 (INDEXNASDAQ: NDX), giving investors exposure to 100 of the largest companies on the NASDAQ exchange.
However, LNAS is also leverage, meaning it is designed to amplify the gains or losses of the index it tracks. Sadly for investors, FY 2022 was a negative one for the NASDAQ. And due to LNAS's leveraged nature, investors suffered a 49.99% loss as a result.
